Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Medical training in research: A challenge].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same author

[Clinical and obstetric characteristics in women with multiple sclerosis during pregnancy].

Revista medica del Instituto Mexicano del Seguro Social·2026
Same author

Longitudinal evolution of JC virus serological index in multiple sclerosis patients treated with natalizumab: Observational dynamics in a decade-spanning real-world cohort (2014-2024).

Clinical neurology and neurosurgery·2026
Same author

Overexpression of ITGB3 in Peripheral Blood Mononuclear Cells of Relapsing-Remitting Multiple Sclerosis Patients.

International journal of molecular sciences·2025
Same author

Factors associated with cognitive impairment in patients with neuromyelitis optica spectrum disorders from Mexico.

Multiple sclerosis journal - experimental, translational and clinical·2025
Same author

Inflammatory Joint Pathologies and the Oral-Gut Microbiota: A Reason for Origin.

Healthcare (Basel, Switzerland)·2025

Related Experiment Video

Updated: Aug 19, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K

Neuromyelitis optica spectrum disorder: pathophysiological approach.

Mario A Mireles-Ramírez1, Fermín P Pacheco-Moises2, Héctor A González-Usigli1

  • 1Department of Neurology, High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara, Jalisco, Mexico.

The International Journal of Neuroscience
|December 1, 2022
PubMed
Summary

Neuromyelitis Optica Spectrum Disorder (NMOSD) involves inflammation and demyelination, often linked to aquaporin-4 (AQP4) autoantibodies. Identifying these antibodies is crucial for diagnosing NMOSD and guiding treatment, differentiating it from multiple sclerosis.

Keywords:
AQP4 proteinAnti-AQP4 autoantibodiesDevic’s neuromyelitis opticaEAAT2 neurotransmitter transportercerebrospinal fluid

More Related Videos

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.2K
Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

7.2K

Related Experiment Videos

Last Updated: Aug 19, 2025

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

11.6K
Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

14.2K
Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis
09:01

Flow Cytometric Analysis of Lymphocyte Infiltration in Central Nervous System during Experimental Autoimmune Encephalomyelitis

Published on: November 17, 2020

7.2K

Area of Science:

  • Neuroimmunology
  • Neuropathology
  • Autoimmune diseases

Background:

  • Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe inflammatory and demyelinating central nervous system disease.
  • Pathology primarily affects optic nerves and spinal cord, but can involve brainstem and hypothalamus.
  • Disease course is characterized by severe relapses with incomplete recovery.

Purpose of the Study:

  • To review pathological findings in NMOSD, particularly those associated with aquaporin-4 (AQP4) autoantibodies.
  • To elucidate mechanisms of astrocyte dysfunction and demyelination in NMOSD.
  • To differentiate NMOSD from other neurological conditions like multiple sclerosis.

Main Methods:

  • Comprehensive literature search of the National Center for Biotechnology Information database.
  • Systematic review of studies published up to July 2022.
  • Analysis of pathological findings and immunological markers in NMOSD.

Main Results:

  • NMOSD is associated with autoantibodies to aquaporin-4 (AQP4-IgG), which target astrocyte water channels.
  • AQP4 autoantibodies bind to orthogonal arrays of particles (OAPs) on astrocytes, activating complement and causing demyelination.
  • Damage to AQP4 channels leads to water influx, necrosis, and axonal loss.
  • Some NMOSD patients are seronegative for AQP4-IgG but positive for myelin oligodendrocyte glycoprotein antibodies.

Conclusions:

  • NMOSD is an astrocytopathy, distinct from multiple sclerosis, with AQP4-IgG as a key serological marker.
  • The disease involves complement-dependent cytotoxicity and neuroinflammation.
  • Detection of AQP4 or other autoantibodies is critical for accurate diagnosis and effective immunosuppressant therapy.